12,22–24 The first CPVT transgenic mouse model was produced by Priori’s group in 2005. These authors introduced the RyR2 inhibitor price R4496C mutation into the mouse genome by homologous recombination and successfully reproduced the human phenotype.24 This in-vivo model proved the concept that RyR2 mutations may cause polymorphic and bidirectional Inhibitors,research,lifescience,medical ventricular tachycardia in a knock-in mouse model and mimic the clinical phenotype of CPVT patients.24 Subsequently, Priori’s group demonstrated that myocytes isolated from the heart of the RyR2 R4496C knock-in mouse generated DADs and triggered activity upon exposure to β-adrenergic stimulation, while the control myocytes isolated from wild-type

mouse did not.25 Similar results were reported by Kannankeril et al. who generated a knock-in mouse model of RyR2 R176Q mutation and demonstrated the disease phenotype in vivo and in vitro.26 Priori’s group was also the first to generate in-vitro modeling of the

CASQ2 D307H mutation Inhibitors,research,lifescience,medical using infected rat myocytes with adenoviruses engineered to express the sellectchem mutated CASQ2. In this study the authors demonstrated that the mutated myocytes developed DADs upon adrenergic stimulation while the control myocytes did not, as shown in Figure 2. This model provided the first evidence that mutant CASQ2 can generate DADs.12 Inhibitors,research,lifescience,medical Using the same model of rat myocytes infected with adenoviruses, Terentyev et al. and di Barletta el al. generated in-vitro models of the CASQ2 R33Q and L167H mutations, respectively, and reported on the generation of DADs in the mutated myocytes.22,23 Nonetheless, these models suffer from several limitations because the Inhibitors,research,lifescience,medical myocytes express both the mutant and the endogenous wild-type CASQ2. Inhibitors,research,lifescience,medical In 2006, Knollmann et al. generated CASQ2-null (CASQ2−/−) mice which were viable and exhibited the human-like arrhythmias. Despite the absence of CASQ2, these animals maintained relatively normal Ca2+ release and contractile function. However, myocytes isolated from these mice had

exceptional increases in SR volume, increased gain of Ca2+-induced SR Ca2+ release, and increased diastolic SR Ca2+ leak.27 Other transgenic models with deficient RyR2 or CASQ2 genes were generated and have confirmed the correlation between the arrhythmogenic phenotype to the mutant genes, although the Drug_discovery observed phenotype did not always resemble the human disease.28 Figure 2 Disturbances in rhythmic [Ca2+]i transients and membrane potential induced by ISO in myocytes expressing CASQ2D307H. HUMAN MODELS OF CPVT The recent discovery of genomic reprogramming of human somatic cells into induced pluripotent stem cells (iPSC) offers an innovative and practical approach to study inherited diseases including heart pathologies. Induced pluripotent stem cells are the product of somatic cell reprogramming to an embryonic-like state.